Cargando…
Lymph node dissection during nephroureterectomy: Establishing the existing evidence based on a review of the literature
Abstract Objective: To determine the role of lymph node dissection (LND) in the treatment of upper tract transitional cell carcinoma (UTTCC), as the role of LND along with nephroureterectomy in treating UTTCC is unclear and several retrospective studies have been published on this topic with conflic...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711077/ https://www.ncbi.nlm.nih.gov/pubmed/31489232 http://dx.doi.org/10.1080/2090598X.2019.1596401 |
_version_ | 1783446457905315840 |
---|---|
author | Grimes, Nathan McKay, Alastair Lee, Su-Min Aboumarzouk, Omar M. |
author_facet | Grimes, Nathan McKay, Alastair Lee, Su-Min Aboumarzouk, Omar M. |
author_sort | Grimes, Nathan |
collection | PubMed |
description | Abstract Objective: To determine the role of lymph node dissection (LND) in the treatment of upper tract transitional cell carcinoma (UTTCC), as the role of LND along with nephroureterectomy in treating UTTCC is unclear and several retrospective studies have been published on this topic with conflicting results. Methods: The Medical Literature Analysis and Retrieval System Online (MEDLINE), the Excerpta Medica dataBASE (EMBASE), Cochrane Central Register of Controlled Trials database (CENTRAL), Cumulative Index to Nursing and Allied Health Literature (CINAHL), Clinicaltrials.gov, Google Scholar, and individual urological journals, were searched for all studies investigating the role of LND in the treatment of UTTCC. Of the studies identified, those that met inclusion criteria were included in this review. Results: In all, 27 studies were included in this review, with 9303 patients who underwent LND. No randomised controlled trials (RCTs) were identified. Tumours were located in the renal pelvis in 62% of patients, in the ureter in 35.5%, and multifocal in 2.3%. In total: 77.1% were LN-negative and 22.9% had LN metastasis. For all patients undergoing LND, the 5-year recurrence-free survival (RFS) and cancer-specific survival (CSS) rates were 27–65.4% and 32.3–95%, respectively. For patients who underwent a LND in accordance with a standardised anatomical template, the 5-year RFS and CSS rates were 84.3–93% and 83.5–94%, respectively. Conclusion: LND may provide a survival benefit in patients undergoing nephroureterectomy for UTTCC, particularly if following a standardised anatomical template and in those patients with muscle-invasive disease; however, a prospective RCT is required to confirm this. Abbreviations: CSS: cancer-specific survival; LN(D): lymph node (dissection); MeSH: Medical Subject Headings; OS: overall survival; pT: pathological T stage; RCT: randomised controlled trial; RFS: recurrence-free survival; UTTCC: upper tract TCC |
format | Online Article Text |
id | pubmed-6711077 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-67110772019-09-05 Lymph node dissection during nephroureterectomy: Establishing the existing evidence based on a review of the literature Grimes, Nathan McKay, Alastair Lee, Su-Min Aboumarzouk, Omar M. Arab J Urol Oncology/Reconstruction Abstract Objective: To determine the role of lymph node dissection (LND) in the treatment of upper tract transitional cell carcinoma (UTTCC), as the role of LND along with nephroureterectomy in treating UTTCC is unclear and several retrospective studies have been published on this topic with conflicting results. Methods: The Medical Literature Analysis and Retrieval System Online (MEDLINE), the Excerpta Medica dataBASE (EMBASE), Cochrane Central Register of Controlled Trials database (CENTRAL), Cumulative Index to Nursing and Allied Health Literature (CINAHL), Clinicaltrials.gov, Google Scholar, and individual urological journals, were searched for all studies investigating the role of LND in the treatment of UTTCC. Of the studies identified, those that met inclusion criteria were included in this review. Results: In all, 27 studies were included in this review, with 9303 patients who underwent LND. No randomised controlled trials (RCTs) were identified. Tumours were located in the renal pelvis in 62% of patients, in the ureter in 35.5%, and multifocal in 2.3%. In total: 77.1% were LN-negative and 22.9% had LN metastasis. For all patients undergoing LND, the 5-year recurrence-free survival (RFS) and cancer-specific survival (CSS) rates were 27–65.4% and 32.3–95%, respectively. For patients who underwent a LND in accordance with a standardised anatomical template, the 5-year RFS and CSS rates were 84.3–93% and 83.5–94%, respectively. Conclusion: LND may provide a survival benefit in patients undergoing nephroureterectomy for UTTCC, particularly if following a standardised anatomical template and in those patients with muscle-invasive disease; however, a prospective RCT is required to confirm this. Abbreviations: CSS: cancer-specific survival; LN(D): lymph node (dissection); MeSH: Medical Subject Headings; OS: overall survival; pT: pathological T stage; RCT: randomised controlled trial; RFS: recurrence-free survival; UTTCC: upper tract TCC Taylor & Francis 2019-04-24 /pmc/articles/PMC6711077/ /pubmed/31489232 http://dx.doi.org/10.1080/2090598X.2019.1596401 Text en © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Oncology/Reconstruction Grimes, Nathan McKay, Alastair Lee, Su-Min Aboumarzouk, Omar M. Lymph node dissection during nephroureterectomy: Establishing the existing evidence based on a review of the literature |
title | Lymph node dissection during nephroureterectomy: Establishing the existing evidence based on a review of the literature |
title_full | Lymph node dissection during nephroureterectomy: Establishing the existing evidence based on a review of the literature |
title_fullStr | Lymph node dissection during nephroureterectomy: Establishing the existing evidence based on a review of the literature |
title_full_unstemmed | Lymph node dissection during nephroureterectomy: Establishing the existing evidence based on a review of the literature |
title_short | Lymph node dissection during nephroureterectomy: Establishing the existing evidence based on a review of the literature |
title_sort | lymph node dissection during nephroureterectomy: establishing the existing evidence based on a review of the literature |
topic | Oncology/Reconstruction |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711077/ https://www.ncbi.nlm.nih.gov/pubmed/31489232 http://dx.doi.org/10.1080/2090598X.2019.1596401 |
work_keys_str_mv | AT grimesnathan lymphnodedissectionduringnephroureterectomyestablishingtheexistingevidencebasedonareviewoftheliterature AT mckayalastair lymphnodedissectionduringnephroureterectomyestablishingtheexistingevidencebasedonareviewoftheliterature AT leesumin lymphnodedissectionduringnephroureterectomyestablishingtheexistingevidencebasedonareviewoftheliterature AT aboumarzoukomarm lymphnodedissectionduringnephroureterectomyestablishingtheexistingevidencebasedonareviewoftheliterature |